Accessibility Tools

Skip to main content

November 2025, Vol 2, No 10

A Veteran’s Journey: 20-Year Survivor Advocates for Lung Cancer Awareness and Screening
Feature Focus
November 2025, Vol 2, No 10
For Jim Pantelas—a veteran, advocate, and 20-year lung cancer survivor—his diagnosis marked the start of a journey filled with resilience, hope, and purpose. His remarkable story highlights the power of determination, the life-saving impact of new treatments, and his dedication to improving awareness and care for others, especially veterans. Read More ›
Reflecting on Our First Year
Introduction
November 2025, Vol 2, No 10
As we step into November, a month rich with significance, I am honored to introduce myself as the new Editorial Director of ImPACT Read More ›
TRICARE Provides Guidance for National Guard and Reserve Members Seeking Line of Duty Care
TRICARE News Roundup
November 2025, Vol 2, No 10
TRICARE outlines the process for National Guard and Reserve members to access medical care for injuries, illnesses, or diseases sustained during service. Read More ›
TRICARE Supports Management of Chronic Health Conditions
TRICARE News Roundup
November 2025, Vol 2, No 10
Managing chronic health conditions like diabetes, asthma, hypertension, or heart disease can be challenging, but TRICARE offers various resources to help beneficiaries improve their health and quality of life. Read More ›
Lung Cancer Screening at VA Northern California: Real-World Insights Into High-Risk Lung-RADS 4 Nodules
Conference Highlights
November 2025, Vol 2, No 10
Lung cancer screening (LCS) programs have demonstrated the ability to detect malignancies earlier, allowing for potentially curative treatment. Read More ›
Study Questions Role of Maintenance Pemetrexed in Advanced Nonsquamous NSCLC
Conference Highlights
November 2025, Vol 2, No 10
A retrospective cohort study presented at the 2025 World Conference on Lung Cancer raises questions about the necessity of combining maintenance pemetrexed (Alimta) with pembrolizumab (Keytruda) in the treatment of advanced nonsquamous non–small cell lung cancer (NSCLC). Read More ›
FDA Approves Lurbinectedin and Atezolizumab Combination for Extensive-Stage Small Cell Lung Cancer
FDA Approvals
November 2025, Vol 2, No 10
On October 2, 2025, the FDA approved lurbinectedin (Zepzelca) in combination with atezolizumab (Tecentriq) or atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) for the maintenance treatment of adults with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first-line induction therapy with atezolizumab, carboplatin, and etoposide. Read More ›
FDA Approves Imlunestrant for ESR1-Mutated Advanced Breast Cancer
FDA Approvals
November 2025, Vol 2, No 10
On September 25, 2025, the FDA approved imlunestrant (Inluriyo) for the treatment of advanced or metastatic breast cancer that is estrogen receptor (ER)-positive, HER2-negative, and ESR1-mutated. Read More ›
FDA Approves Subcutaneous Formulation of Pembrolizumab (Keytruda Qlex) for Solid Tumors
FDA Approvals
November 2025, Vol 2, No 10
On September 19, 2025, the FDA approved pembrolizumab and berahyaluronidase alfapmph (Keytruda Qlex) for subcutaneous injection in adult and pediatric patients (12 years and older) with solid tumor indications previously approved for the intravenous formulation of pembrolizumab (Keytruda). Read More ›